These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 30945698

  • 1. Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles.
    Długosz-Danecka M, Szmit S, Kocurek A, Koźlik P, Giza A, Zimowska-Curyło D, Małkowski B, Sowa-Staszczak A, Kużdżał J, Jurczak W.
    Pol Arch Intern Med; 2019 Apr 30; 129(4):259-266. PubMed ID: 30945698
    [Abstract] [Full Text] [Related]

  • 2. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, Ben-Bassat I, Nagler A, Avigdor A.
    Acta Haematol; 2016 Apr 30; 135(3):156-61. PubMed ID: 26588173
    [Abstract] [Full Text] [Related]

  • 3. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
    Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben-Bassat I, Polliack A.
    Ann Oncol; 2010 Jan 30; 21(1):126-32. PubMed ID: 19608615
    [Abstract] [Full Text] [Related]

  • 4. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
    Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A.
    J Clin Oncol; 2018 Feb 10; 36(5):454-462. PubMed ID: 29360414
    [Abstract] [Full Text] [Related]

  • 5. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B.
    Cochrane Database Syst Rev; 2017 May 25; 5(5):CD007941. PubMed ID: 28541603
    [Abstract] [Full Text] [Related]

  • 6. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
    Wannesson L, Bargetzi M, Cairoli A, Cerutti A, Heim D, Hess U, Lerch E, Pabst T, Renner C, Samaras P, Zucca E.
    Leuk Lymphoma; 2013 Jan 25; 54(1):36-40. PubMed ID: 22702653
    [Abstract] [Full Text] [Related]

  • 7. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.
    Br J Haematol; 2017 Sep 25; 178(5):709-718. PubMed ID: 28589704
    [Abstract] [Full Text] [Related]

  • 8. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
    Belada D, Štěpánková P, Sýkorová A, Žák P, Smolej L.
    Leuk Lymphoma; 2015 Jul 25; 56(7):2013-8. PubMed ID: 25330440
    [Abstract] [Full Text] [Related]

  • 9. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
    J Clin Oncol; 2011 Nov 10; 29(32):4234-42. PubMed ID: 21990399
    [Abstract] [Full Text] [Related]

  • 10. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
    Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW.
    Blood; 2019 Oct 10; 134(15):1238-1246. PubMed ID: 31331918
    [Abstract] [Full Text] [Related]

  • 11. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.
    Lancet Haematol; 2021 Apr 10; 8(4):e278-e288. PubMed ID: 33770483
    [Abstract] [Full Text] [Related]

  • 12. Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).
    Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H.
    Cancer Sci; 2024 Oct 10; 115(10):3384-3393. PubMed ID: 39034771
    [Abstract] [Full Text] [Related]

  • 13. Sarcoidosis following escalated BEACOPP chemotherapy for stage IV Hodgkin lymphoma.
    Cho KK, Lyes SM, Shetty A.
    Intern Med J; 2019 Apr 10; 49(4):547-548. PubMed ID: 30957369
    [No Abstract] [Full Text] [Related]

  • 14. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
    Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, Massey V, Children's Oncology Group.
    Ann Oncol; 2002 Apr 10; 13 Suppl 1():107-11. PubMed ID: 12078889
    [Abstract] [Full Text] [Related]

  • 15. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
    Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Sibon D, Bonnet C, Berriolo-Riedinger A, Edeline V, Parrens M, Damotte D, Coso D, André M, Meignan M, Rossi C.
    J Clin Oncol; 2022 Apr 01; 40(10):1091-1101. PubMed ID: 34990281
    [Abstract] [Full Text] [Related]

  • 16. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Brière J, Clément-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N.
    Cancer Med; 2020 Sep 01; 9(18):6565-6575. PubMed ID: 32710498
    [Abstract] [Full Text] [Related]

  • 17. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.
    Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, Weiner M.
    Blood; 2011 Mar 03; 117(9):2596-603. PubMed ID: 21079154
    [Abstract] [Full Text] [Related]

  • 18. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P.
    Hematol Oncol Clin North Am; 2014 Feb 03; 28(1):65-74. PubMed ID: 24287068
    [Abstract] [Full Text] [Related]

  • 19. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
    Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie.
    Lancet; 2012 May 12; 379(9828):1791-9. PubMed ID: 22480758
    [Abstract] [Full Text] [Related]

  • 20. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.